Impact of simplified HCV diagnostic strategies on HCV epidemic among MSM in Taiwan: a modelling study

Joyce Huei-Jiuan Wu | 15 March 2023 Surveillance, Evaluation, and Research Program (SERP) Kirby Institute, UNSW Sydney



HCV epidemic in MSM globally & in Taiwan


	Prevalence in general population, %	Overall prevalence in MSM		HIV-negative		HIV-positive	
		Pooled prevalence, %	PR (95% CI)	Pooled prevalence, %	PR (95% CI)	Pooled prevalence, %	PR (95% CI)
(Continued from previous page)							
Western Pacific region	NA	2.7%	1.29 (0.91–1.67)	1.4%	2.68 (1.63-3.74)	6.5%	5·10 (3·23–6·96)
Australia	1.30%	2.8%	2.16 (1.78-2.61)	0.8%	0.61 (0.32-1.07)	8.7%	6.70 (5.83-7.66)
China	1.21%	1.0%	0.83 (0.76-0.89)	0.5%	0.41 (0.28-0.58)	2.8%	2-34 (1-39-3-70)
Taiwan	3.28%	3.5%	1.07 (0.97–1.18)	0.7%	0.22 (0.11-0.41)	4.5%	1-37 (1-25-1-50)
Japan	0.98%	2.1%	2.10 (1.32-3.18)	NA		2.1%	2.10 (1.32-3.18)
Mongolia	9.80%	18.0%	1.84 (0.84-3.49)	18.0%	1.84 (0.84–3.49)	NA	
Singapore	1.70%	0-0%	0.00 (0.00-0.83)	NA		0.0%	0.00 (0.00-0.83)
South Korea	1.30%	4.1%	3.13 (1.66–5.34)	NA		4.1%	3·13 (1·66–5·34)
Vietnam	1.49%	24.6%	16.53 (14.97-28.20)	21.9%	14.67 (13.01-16.49)	55-2%	37-01 (32-16-42-38)
Overall	NA	3-3%	3·04 (2·55-3·53)	1.4%	1.58 (1.14–2.01)	6-3%	6-22 (5-14-7-29)





The long journey to access to HCV treatment in Taiwan

- DAAs has been reimbursed to all HCV patients by National Health Insurance (NHI) Program since 2019
 - All doctors can prescribe DAAs without referring to hepatologists since October 2021
- Access to diagnosis and treatment is low
 - Access to HCV testing is varied based on the engagement of health services
 - Complexity of the current diagnostic algorithm's complexity for HCV







Simplified HCV testing strategies in Taiwan

- Point-of-care antibody testing
- One-step point-of-care RNA testing
- S Dried blood spot testing
- Clinic-based reflex RNA testing




Model overview






HCV care cascade



HCV disease progress

Population structure





(irbv Institute

Model outcomes and sensitivity analysis

Model outcomes


- HCV incidence
- Percentage of HCV diagnosis and treatment

We varied the following parameters to investigate its impact on HCV epidemic


- The scale-up time frame of HCV testing scenario
- The effect of simplified HCV testing strategy
- HCV reinfection rate
- Targeted at MSM subgroups who regularly engaged with HIV prevention and care services




Results-baseline model projection








Results-impact of simplified HCV testing strategies




Testing scenarios



Results-sensitivity analysis

Kirby Institute



Conclusion

- All simplified HCV testing strategies reduce HCV incidence and improve the HCV diagnosis and treatment.
 - Impact: Single visit point-of-care RNA testing > Clinic-based RNA testing > Dried blood spot testing > point-of-care antibody testing
- Reinfection are crucial to the impact of simplified HCV testing strategies
- None of the simplified HCV testing strategies could achieve the WHO elimination impact target among entire population of MSM



Implications

- Inform national/regional action planning for HCV on simplified HCV testing targeted at MSM for Taiwan and the Western Pacific
- This mathematical model could also be used in other settings in the region to evaluate the impact of simplified strategies on HCV testing and treatment.



Acknowledgement

Kirby Institute

- Richard Gray
- Sophy Shih
- Tanya Applegate
- Jason Grebely
- Amy Known
- Evan Cunningham

WHO country office-India

Po-lin Chen

National Hepatitis C Program Office, Ministry of Health and Welfare, Taipei, Taiwan

- Raoh-Fang Pwu
- Grace Hui-Min Wu
- Wen-Wen Yang

National Cheng Kung University Hospital, Tainan, Taiwan

Pin-Nan Cheng



